Author: admin

DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast

Some of the key facts of the Hidradenitis Suppurativa Market Report: 

• The Hidradenitis Suppurativa market size was valued ~USD 1,400 million in 2023 and is expected to grow with a significant CAGR during the study period (2020-2034)

• The highest Hidradenitis Suppurativa market size was valued in the United States accounting for approximately USD 1,100 million in 2023 and is expected to grow by 2034.

• In 2023, Germany had the largest market size among the EU4 countries, totaling approximately USD ~100 million. Conversely, Spain had the smallest market size, estimated at around USD 40 million in the same year.

• In 2023, the total number of prevalent Hidradenitis Suppurativa cases in the 7MM was approximately 6.2 million. This figure is expected to rise by 2034.

• In the 7MM, the US had the largest number of diagnosed prevalent cases of Hidradenitis Suppurativa, reaching around 877,600 in 2023.

• Until 2023, HUMIRA held a significant market share in the treatment of hidradenitis suppurativa (HS) in the US. However, in October 2023, the US FDA approved COSENTYX for the management of moderate to severe HS in adults. COSENTYX stands as the sole FDA-approved fully human biologic that directly targets interleukin-17A (IL-17A), a cytokine implicated in the inflammation associated with Hidradenitis Suppurativa.

• In 2023, the estimated total prevalent cases of Hidradenitis Suppurativa in the US were around 3 million, with an anticipated increase projected during the study period spanning from 2020 to 2034.

• Among all the countries, the 30–39 age group showed the largest proportion of the Hidradenitis Suppurativa prevalent pool, representing almost 25% of the total cases. Conversely, the 0-17 age group had the lowest number of cases, accounting for approximately 2%.

• Key Hidradenitis Suppurativa Companies: AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others

• Key Hidradenitis Suppurativa Therapies: HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others

• The Hidradenitis Suppurativa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hidradenitis Suppurativa pipeline products will significantly revolutionize the Hidradenitis Suppurativa market dynamics.

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful, recurrent nodules or abscesses that develop in areas where skin rubs together, such as the armpits, groin, buttocks. These nodules can rupture and lead to the formation of sinus tracts or tunnels under the skin, which can result in the development of draining fistulas and scarring.

Get a Free sample for the Hidradenitis Suppurativa Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market

Hidradenitis Suppurativa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hidradenitis Suppurativa Epidemiology Segmentation:

The Hidradenitis Suppurativa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Hidradenitis Suppurativa

• Prevalent Cases of Hidradenitis Suppurativa by severity

• Gender-specific Prevalence of Hidradenitis Suppurativa

• Diagnosed Cases of Episodic and Chronic Hidradenitis Suppurativa

Download the report to understand which factors are driving Hidradenitis Suppurativa epidemiology trends @ Hidradenitis Suppurativa Epidemiology Forecast

Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched during the study period. The analysis covers Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hidradenitis Suppurativa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hidradenitis Suppurativa Therapies and Key Companies

• HUMIRA: AbbVie

• COSENTYX (secukinumab): Novartis Pharmaceuticals

• BIMZELX (bimekizumab): UCB Biopharma

• Eltrekibart (LY3041658): Eli Lilly

• ROCEPHIN: Institut Pasteur

• Bimekizumab: UCB Biopharma SRL

• Sonelokimab: MoonLake Immunotherapeutics

• Izokibep: ACELYRIN Inc.

• CFZ533: Novartis

• PTM-001: Phoenicis Therapeutics

• Eltrekibart: Eli Lilly and Company

• Upadacitinib: AbbVie

• Deucravacitinib: Beth Israel Deaconess Medical Center

• secukinumab: Novartis

• SAR442970: Sanofi

• Spesolimab: Boehringer Ingelheim

• SAR444656: Sanofi

• Lutikizumab: AbbVie

• Povorcitinib: Incyte Corporation

Discover more about therapies set to grab major Hidradenitis Suppurativa market share @ Hidradenitis Suppurativa Treatment Landscape

Scope of the Hidradenitis Suppurativa Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hidradenitis Suppurativa Companies: AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others

• Key Hidradenitis Suppurativa Therapies: HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others

• Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies

• Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hidradenitis Suppurativa Unmet Needs, KOL’s views, Analyst’s views, Hidradenitis Suppurativa Market Access and Reimbursement 

To know more about Hidradenitis Suppurativa companies working in the treatment market, visit @ Hidradenitis Suppurativa Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Hidradenitis Suppurativa Market Report Introduction

2. Executive Summary for Hidradenitis Suppurativa

3. SWOT analysis of Hidradenitis Suppurativa

4. Hidradenitis Suppurativa Patient Share (%) Overview at a Glance

5. Hidradenitis Suppurativa Market Overview at a Glance

6. Hidradenitis Suppurativa Disease Background and Overview

7. Hidradenitis Suppurativa Epidemiology and Patient Population

8. Country-Specific Patient Population of Hidradenitis Suppurativa 

9. Hidradenitis Suppurativa Current Treatment and Medical Practices

10. Hidradenitis Suppurativa Unmet Needs

11. Hidradenitis Suppurativa Emerging Therapies

12. Hidradenitis Suppurativa Market Outlook

13. Country-Wise Hidradenitis Suppurativa Market Analysis (2020–2034)

14. Hidradenitis Suppurativa Market Access and Reimbursement of Therapies

15. Hidradenitis Suppurativa Market Drivers

16. Hidradenitis Suppurativa Market Barriers

17.  Hidradenitis Suppurativa Appendix

18. Hidradenitis Suppurativa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake

“Sepsis Clinical Trials”

(Albany, United States) Sepsis pipeline constitutes 25+ key companies continuously working towards developing 30+ Sepsis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Sepsis Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sepsis Market.

The Sepsis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Sepsis Pipeline Analysis

Some of the key takeaways from the Sepsis Pipeline Report:

• Sepsis Companies across the globe are diligently working toward developing novel Sepsis treatment therapies with a considerable amount of success over the years. 
• Sepsis companies working in the treatment market are AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics and others, are developing therapies for the Sepsis treatment 
• Emerging Sepsis therapies such as Enibarcimab, M 6229, SNIPR 001, and others are expected to have a significant impact on the Sepsis market in the coming years.
• In April 2024, Enlivex announced the 28-topline data from the Phase II trial evaluating ALLOCETRA.
• In April 2024, AdrenoMed announced that the US FDA granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment of septic shock.

Sepsis Overview

Sepsis is a life-threatening medical condition that arises when the body’s response to an infection causes widespread inflammation. This inflammation can lead to tissue damage, organ failure, and death if not promptly treated. Sepsis is most commonly triggered by bacterial infections but can also result from viral, fungal, or parasitic infections. The condition progresses through three stages: sepsis, severe sepsis, and septic shock. Symptoms of sepsis include fever, increased heart rate, rapid breathing, and confusion. As it advances, symptoms may escalate to include significant drop in blood pressure, difficulty breathing, and potential organ dysfunction.

Prompt diagnosis and treatment are critical in managing sepsis. Treatment typically involves antibiotics to combat the infection, intravenous fluids to maintain blood pressure and hydration, and other supportive measures such as oxygen therapy or mechanical ventilation if needed. Early detection through awareness of symptoms and rapid intervention can significantly improve outcomes. Preventative measures include proper hygiene, timely vaccination, and infection control practices in healthcare settings. Despite advances in medical care, sepsis remains a leading cause of death globally, highlighting the need for ongoing research and improved clinical protocols to enhance early detection and treatment.

Get a Free Sample PDF Report to know more about Sepsis Pipeline Therapeutic Assessment- Sepsis Treatment Market

Sepsis Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sepsis Molecule Type

Sepsis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Sepsis Pipeline Therapeutics Assessment

• Sepsis Assessment by Product Type
• Sepsis By Stage and Product Type
• Sepsis Assessment by Route of Administration
• Sepsis By Stage and Route of Administration
• Sepsis Assessment by Molecule Type
• Sepsis by Stage and Molecule Type

DelveInsight’s Sepsis Report covers around 30+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sepsis product details are provided in the report. Download the Sepsis pipeline report to learn more about the emerging Sepsis therapies- Sepsis Therapeutics Market

Sepsis Pipeline Analysis:

The Sepsis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Sepsis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.
• Sepsis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sepsis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sepsis market.

Download Sample PDF Report to know more about Sepsis drugs and therapies- Sepsis Clinical Trials and FDA Approvals

Scope of Sepsis Pipeline Drug Insight    

• Coverage: Global
• Key Sepsis Companies: AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics and others.
• Key Sepsis Therapies: Enibarcimab, M 6229, SNIPR 001, and others.
• Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
• Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers 

Request for Sample PDF Report for Sepsis Pipeline Assessment and clinical trials – Sepsis Drugs in Pipeline

Table of Contents

1. Sepsis Report Introduction

2. Sepsis Executive Summary

3. Sepsis Overview                                 

4. Sepsis- Analytical Perspective In-depth Commercial Assessment

5. Sepsis Pipeline Therapeutics

6. Sepsis Late Stage Products (Phase II/III)

7. Sepsis Mid Stage Products (Phase II)

8. Sepsis Early Stage Products (Phase I)

9. Sepsis Preclinical Stage Products

10. Sepsis Therapeutics Assessment

11. Sepsis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sepsis Companies

14. Sepsis Key Products

15. Sepsis Unmet Needs

16 . Sepsis Market Drivers and Barriers

17. Sepsis Future Perspectives and Conclusion

18. Sepsis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sepsis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medications, Treatment Market, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

“Multiple Sclerosis Clinical Trials”

(Albany, USA) DelveInsight’s Multiple Sclerosis Pipeline report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Multiple sclerosis pipeline landscape.

“Multiple sclerosis Pipeline Insight, 2024” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple sclerosis pipeline landscape is provided which includes the disease overview and Multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Request a sample and discover the recent advances in Multiple Sclerosis Treatment Drugs @ Multiple Sclerosis Pipeline Outlook

Key Takeaways from the Multiple Sclerosis Pipeline Report

• DelveInsight’s Multiple Sclerosis pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Multiple Sclerosis treatment.
• The leading companies working in the Multiple Sclerosis Market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Promising Multiple Sclerosis Pipeline Therapies in the various stages of development rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others.
• In November 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
• October 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
• September 2023: ImStem Biotechnology announced a study of phase 1 clinical trials for IMS001. This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.

Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, Visit @ Multiple Sclerosis Treatment Market

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, specifically the brain and spinal cord. It occurs when the immune system mistakenly attacks the protective myelin sheath covering nerve fibers, leading to communication problems between the brain and the rest of the body. Over time, the disease can cause permanent damage or deterioration of the nerves themselves.

Multiple sclerosis manifests in various forms, with relapsing-remitting Multiple sclerosis (RRMS) being the most common. RRMS is characterized by episodes of new or worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions). Other types include primary progressive Multiple sclerosis (PPMS), which involves steady progression without relapses, and secondary progressive Multiple sclerosis (SPMS), which follows an initial relapsing-remitting course and then transitions to a progressive form.

Symptoms of Multiple sclerosis vary widely and can include fatigue, numbness or tingling, muscle weakness, coordination and balance issues, vision problems, and cognitive changes. The exact cause of Multiple sclerosis remains unknown, though it is believed to result from a combination of genetic and environmental factors.

There is no cure for Multiple sclerosis, but treatments are available to manage symptoms, reduce relapses, and slow disease progression. These treatments include disease-modifying therapies, corticosteroids, physical therapy, and various medications to address specific symptoms. Early diagnosis and intervention are crucial for improving long-term outcomes.

Find out more about Multiple Sclerosis Therapeutics Assessment @ Multiple Sclerosis Clinical Trials and FDA Approvals

Multiple Sclerosis Emerging Drugs Profile

• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION

Multiple Sclerosis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Multiple sclerosis therapies. The Multiple sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.

DelveInsight’s Multiple Sclerosis Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample Report @ Multiple Sclerosis Drugs Assessment

Route of Administration

Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Multiple Sclerosis Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn more about the emerging Multiple Sclerosis Pipeline Therapies @ Multiple Sclerosis Clinical Trials Assessment

Scope of the Multiple Sclerosis Pipeline Report

• Coverage- Global
• Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Multiple Sclerosis Pipeline Therapies- HIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others

Table of Content

1. Introduction
2. Executive Summary
3. Multiple sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Ublituximab: TG Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EHP 101: Emerald Health Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ASLAN 003: ASLAN Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Lucid MS: FSD Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple sclerosis Key Companies
21. Multiple sclerosis Key Products
22. Multiple sclerosis- Unmet Needs
23. Multiple sclerosis- Market Drivers and Barriers
24. Multiple sclerosis- Future Perspectives and Conclusion
25. Multiple sclerosis Analyst Views
26. Multiple sclerosis Key Companies
27. Appendix

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medications, Treatment Market, Therapies, Statistics, MOA, ROA and Companies by DelveInsight

“Asthma Clinical Trials”

(Albany, USA) Asthma Pipeline Insight offers in-depth analysis of over 90+ companies and more than 100+ pipeline medications within the Asthma treatment landscape.

DelveInsight’s ‘Asthma Pipeline Insight 2024’ report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain.

To know more about the Asthma pipeline report, click here @ Asthma Pipeline Analysis

Key Takeaways from the Asthma Pipeline Report

• DelveInsight’s asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment. 
• Leading asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape.
• Emerging asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
• On February 2024, AstraZeneca announced results of a Prospective, Observational, Real-World Evidence Study (ASCENT): Asthma Control in Severe Asthma Patients Treated With Tezepelumab.
• On November 2023, Regeneron Pharmaceuticals announced results of a study whose aim is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
• On February 2024, AstraZeneca announced results of a Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.
• On November 2023, GlaxoSmithKline announced results of a 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
• In February 2023, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.

Request a sample and discover the recent advances in asthma drug treatment @ Asthma Treatment Market

Asthma Overview

Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections. 

A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.

Find out more about drugs for asthma @ Asthma Therapies and Drugs

Asthma Pipeline Drugs mentioned in the report:

• MM09-MG01: Inmunotek S.L.
• BGF MDI: AstraZeneca
• GSK3511294: GlaxoSmithKline
• FP 025: Foresee Pharmaceuticals
• ADX-629: Aldeyra Therapeutics
• 610: Sunshine Guojian Pharmaceutical
• EDP1867: Evelo Biosciences, Inc.
• CM-326 : Keymed Biosciences
• 9MW1911: Mabwell (Shanghai) Bioscience Co., Ltd.
• Dapansutrile: Olatec Therapeutics
• LNR 125.38: Lanier Biotherapeutics

Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials and FDA Approval

Asthma Therapeutics Assessment

The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Asthma Pipeline Report 

• Coverage: Global 
• Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others.
• Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.

Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Therapeutic Assessment

Table of Contents

1. Asthma Pipeline Report Introduction

2. Asthma Pipeline Report Executive Summary

3. Asthma Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Asthma Clinical Trial Therapeutics

6. Asthma Pipeline: Late Stage Products (Pre-registration)

7. Asthma Pipeline: Late Stage Products (Phase III)

7.1.BGF MDI: AstraZeneca

8. Asthma Pipeline: Mid Stage Products (Phase II)

8.1. GSK3511294: GlaxoSmithKline

9. Asthma Pipeline: Early Stage Products (Phase I)

9.1. CM-326: Keymed Biosciences

10. Asthma Pipeline Therapeutics Assessment

11. Inactive Products in the Asthma Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Asthma Companies

14. Key Products in the Asthma Pipeline

15. Asthma Unmet Needs

16. Asthma Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medications, Therapies, Treatment Market, Statistics, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials”

(Albany, United States) Non Alcoholic Fatty Liver Disease (NAFLD) pipeline constitutes 80+ key companies continuously working towards developing 100+ Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Alcoholic Fatty Liver Disease (NAFLD) Market.

The Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis

Some of the key takeaways from the Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report:

• NAFLD Companies across the globe are diligently working toward developing novel Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies with a considerable amount of success over the years. 
• Non Alcoholic Fatty Liver Disease (NAFLD) companies working in the treatment market are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others, are developing therapies for the Non Alcoholic Fatty Liver Disease (NAFLD) treatment.
• Emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies such as MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non Alcoholic Fatty Liver Disease (NAFLD) market in the coming years.
• On April 2024, Akero Therapeutics, Inc announced results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• On December 2023, Madrigal Pharmaceuticals, Inc announced results of a 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Non Alcoholic Fatty Liver Disease (NAFLD) Overview

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by the accumulation of fat in the liver of individuals who consume little to no alcohol. NAFLD encompasses a spectrum of liver conditions, ranging from simple fatty liver (steatosis) to more severe forms like non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. Risk factors for NAFLD include obesity, insulin resistance, type 2 diabetes, high cholesterol, and metabolic syndrome. The exact cause of NAFLD is not fully understood but is believed to involve a combination of genetic, environmental, and lifestyle factors.

NAFLD often presents without noticeable symptoms in its early stages, but as the condition progresses, individuals may experience fatigue, abdominal discomfort, and enlargement of the liver. Diagnosis typically involves imaging studies such as ultrasound, CT scan, or MRI, along with blood tests to assess liver function and rule out other liver diseases.

Management of NAFLD primarily focuses on lifestyle interventions, including weight loss, regular exercise, and dietary changes aimed at reducing fat accumulation in the liver and improving metabolic health. For individuals with NASH or advanced NAFLD, additional treatments such as medications targeting liver inflammation or fibrosis may be considered. Close monitoring and management of NAFLD are essential to prevent progression to more severe liver complications, including cirrhosis and liver failure.

Get a Free Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutic Assessment @ Non Alcoholic Fatty Liver Disease (NAFLD) Treatment Market

Non Alcoholic Fatty Liver Disease (NAFLD) Route of Administration

Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non Alcoholic Fatty Liver Disease (NAFLD) Molecule Type

Non Alcoholic Fatty Liver Disease (NAFLD) Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics Assessment

• Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Product Type
• Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Product Type
• Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Route of Administration
• Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Route of Administration
• Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Molecule Type
• Non Alcoholic Fatty Liver Disease (NAFLD) by Stage and Molecule Type

DelveInsight’s Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report covers around 100+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non Alcoholic Fatty Liver Disease (NAFLD) product details are provided in the report. Download the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report to learn more about the emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and FDA Approvals

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis:

The Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non Alcoholic Fatty Liver Disease (NAFLD) with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Alcoholic Fatty Liver Disease (NAFLD) Treatment.
• Non Alcoholic Fatty Liver Disease (NAFLD) key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non Alcoholic Fatty Liver Disease (NAFLD) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Alcoholic Fatty Liver Disease (NAFLD) market.

Download Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) drugs and therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market

Scope of Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Drug Insight    

• Coverage: Global
• Key Non Alcoholic Fatty Liver Disease (NAFLD) Companies: Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.
• Key Non Alcoholic Fatty Liver Disease (NAFLD) Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others.
• Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Assessment: Non Alcoholic Fatty Liver Disease (NAFLD) current marketed and Non Alcoholic Fatty Liver Disease (NAFLD) emerging therapies
• Non Alcoholic Fatty Liver Disease (NAFLD) Market Dynamics: Non Alcoholic Fatty Liver Disease (NAFLD) market drivers and Non Alcoholic Fatty Liver Disease (NAFLD) market barriers 

Request for Sample PDF Report for Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment and clinical trials @ Non Alcoholic Fatty Liver Disease (NAFLD) Drugs and Therapies

Table of Contents

1. Non Alcoholic Fatty Liver Disease (NAFLD) Report Introduction
2. Non Alcoholic Fatty Liver Disease (NAFLD) Executive Summary
3. Non Alcoholic Fatty Liver Disease (NAFLD) Overview       
4. Non Alcoholic Fatty Liver Disease (NAFLD)- Analytical Perspective In-depth Commercial Assessment
5. Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics
6. Non Alcoholic Fatty Liver Disease (NAFLD) Late Stage Products (Phase II/III)
7. Non Alcoholic Fatty Liver Disease (NAFLD) Mid Stage Products (Phase II)
8. Non Alcoholic Fatty Liver Disease (NAFLD) Early Stage Products (Phase I)
9. Non Alcoholic Fatty Liver Disease (NAFLD) Preclinical Stage Products
10. Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Assessment
11. Non Alcoholic Fatty Liver Disease (NAFLD) Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non Alcoholic Fatty Liver Disease (NAFLD) Companies
14. Non Alcoholic Fatty Liver Disease (NAFLD) Key Products
15. Non Alcoholic Fatty Liver Disease (NAFLD) Unmet Needs
16. 16 . Non Alcoholic Fatty Liver Disease (NAFLD) Market Drivers and Barriers
17. Non Alcoholic Fatty Liver Disease (NAFLD) Future Perspectives and Conclusion
18. Non Alcoholic Fatty Liver Disease (NAFLD) Analyst Views
19. Appendix
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Celiac Disease Clinical Trials”

(Albany, United States) Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Celiac Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Celiac Disease Pipeline Outlook

Some of the key takeaways from the Celiac Disease Pipeline Report:

• Celiac Disease Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years. 
• Celiac Disease companies working in the treatment market are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others, are developing therapies for the Celiac Disease treatment 

• Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
• On March 2024, Takeda announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
• On March 2024, Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA announced results of a Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease.
• On December 2023, Topas Therapeutics GmbH announced results of a Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease.
• On November 2023, Chugai Pharmaceutical announced results of a Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study).
• On September 2023, Regeneron Pharmaceuticals announced results of a study based on T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge.

Celiac Disease Overview

Celiac disease is an autoimmune disorder triggered by the ingestion of gluten—a protein found in wheat, barley, and rye—in genetically predisposed individuals. When someone with celiac disease consumes gluten, their immune system responds by damaging the lining of the small intestine. This damage impairs the absorption of nutrients from food, leading to various symptoms and potential long-term complications.

Symptoms of celiac disease can vary widely and may include gastrointestinal issues like diarrhea, abdominal pain, bloating, and constipation, as well as non-gastrointestinal symptoms such as fatigue, joint pain, skin rashes, and neurological problems.

Celiac disease Diagnosis typically involves blood tests to check for specific antibodies associated with celiac disease, followed by confirmation through a biopsy of the small intestine to assess for characteristic damage to the intestinal lining.

The primary treatment for celiac disease is strict adherence to a gluten-free diet, which involves avoiding all foods containing wheat, barley, and rye. This typically leads to symptom resolution, intestinal healing, and prevention of complications. Additionally, individuals with celiac disease may benefit from nutritional supplementation and regular monitoring by healthcare professionals to ensure optimal management of the condition and prevent potential deficiencies or complications. 

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment – Celiac disease Treatment Market

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

• AMY02 : AMYRA Biotech AG
• EQ102 : Equillium Bio.
• DONQ52 : Chugai Pharmaceutical Co., Ltd.
• CALY-002 : Calypso Biotech
• Latiglutenase : ImmunogenX, Inc.
• Ordesekimab : Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule 

Celiac Disease Pipeline Therapeutics Assessment

• Celiac Disease Assessment by Product Type
• Celiac Disease By Stage and Product Type
• Celiac Disease Assessment by Route of Administration
• Celiac Disease By Stage and Route of Administration
• Celiac Disease Assessment by Molecule Type
• Celiac Disease by Stage and Molecule Type

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies – Celiac disease Therapeutic Assessment

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
• Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies – Celiac disease Clinical Trials and FDA Approvals

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight    

• Coverage: Global
• Key Celiac Disease Companies: AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others
• Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials – Celiac disease Therapies and Drugs

Table of Contents 

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Clinical Trials 2024 (Updates): EMA, PDMA, FDA Approvals, Therapies, Treatment Market, ROA, MOA and Companies by DelveInsight